Nicole Fett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicole Fett has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Stephanie Mengden Koon
Department of Dermatology, Oregon Health and Science University, Portland, OR
3 shared publicationsDavid J. Margolis
Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
2 shared publicationsEmile Latour
Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland
2 shared publicationsJulie Dhossche
Department of Dermatology, Oregon Health and Science University, Portland, OR
2 shared publicationsKathleen Joy Propert
Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidermiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States
2 shared publicationsKevin Haynes
Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidermiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 74, 126-128
Lenalidomide monotherapy for necrobiotic xanthogranuloma
- 3 June 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 74, 126-128
Open AccessLenalidomide monotherapy for necrobiotic xanthogranuloma
- 11 May 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (10) , 937-940
Generalized Bullous Fixed Drug Eruption due to Clopidogrel Hypersensitivity Successfully Treated Using the Jefferson Procedure
Generalized bullous fixed drug eruption (GBFDE) is a rare variant of fixed drug eruption that is known to clinically mimic Stevens‐Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Numerous medications have been reported to cause GBFDE, including antiplatelet agents like ticagrelor, but few reports exist linking this reaction to clopidogrel specifically. We report a case of a medically complex 80‐year‐old male who was found to have clopidogrel hypersensitivity manifesting as GBFDE based on clinical characteristics and pathology. He was successfully treated using the Jefferson desensitization protocol, which was developed by cardiologists to enable continuation of clopidogrel. While clopidogrel hypersensitivity reactions are well‐reported, there is a shortage of dermatology literature characterizing the clinical characteristics of these rashes and highlighting the use of the Jefferson desensitization protocol. This case reports on an etiology for GBFDE that is rarely observed and emphasizes the importance of histopathology when differentiating this entity from SJS/TEN. It also reports the successful use of the Jefferson protocol for GBFDE secondary to clopidogrel hypersensitivity.
- 11 May 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (10) , 937-940
Generalized Bullous Fixed Drug Eruption due to Clopidogrel Hypersensitivity Successfully Treated Using the Jefferson Procedure
Generalized bullous fixed drug eruption (GBFDE) is a rare variant of fixed drug eruption that is known to clinically mimic Stevens‐Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Numerous medications have been reported to cause GBFDE, including antiplatelet agents like ticagrelor, but few reports exist linking this reaction to clopidogrel specifically. We report a case of a medically complex 80‐year‐old male who was found to have clopidogrel hypersensitivity manifesting as GBFDE based on clinical characteristics and pathology. He was successfully treated using the Jefferson desensitization protocol, which was developed by cardiologists to enable continuation of clopidogrel. While clopidogrel hypersensitivity reactions are well‐reported, there is a shortage of dermatology literature characterizing the clinical characteristics of these rashes and highlighting the use of the Jefferson desensitization protocol. This case reports on an etiology for GBFDE that is rarely observed and emphasizes the importance of histopathology when differentiating this entity from SJS/TEN. It also reports the successful use of the Jefferson protocol for GBFDE secondary to clopidogrel hypersensitivity.
- Open Access
- 8 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 76, 36-40
Atypical cutaneous manifestations of inflammatory bowel disease: A case series
- 8 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 76, 36-40
Open AccessAtypical cutaneous manifestations of inflammatory bowel disease: A case series
- 12 December 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 25 (2) , 213-226
Recent Advances in Treatment of Systemic Sclerosis and Morphea
Systemic sclerosis (SSc) and morphea are autoimmune sclerosing diseases that cause significant morbidity, and in the case of SSc, mortality. The pathogenesis of both SSc and morphea share vascular dysfunction, auto-reactive T cells and Th2-associated cytokines, such as interleukin 4, and overproduction of transforming growth factor beta (TGFβ). TGFβ stimulates fibroblast collagen and extra-cellular matrix production. Although morphea and SSc have similar pathogenic pathways and histological findings, they are distinct diseases. Recent advances in treatment of morphea, skin sclerosis in SSc, and interstitial lung disease in SSc are focused on targeting known pathogenic pathways.
- 12 December 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 25 (2) , 213-226
Recent Advances in Treatment of Systemic Sclerosis and Morphea
Systemic sclerosis (SSc) and morphea are autoimmune sclerosing diseases that cause significant morbidity, and in the case of SSc, mortality. The pathogenesis of both SSc and morphea share vascular dysfunction, auto-reactive T cells and Th2-associated cytokines, such as interleukin 4, and overproduction of transforming growth factor beta (TGFβ). TGFβ stimulates fibroblast collagen and extra-cellular matrix production. Although morphea and SSc have similar pathogenic pathways and histological findings, they are distinct diseases. Recent advances in treatment of morphea, skin sclerosis in SSc, and interstitial lung disease in SSc are focused on targeting known pathogenic pathways.
- 1 September 2021
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 157 (9) , 1112-1113
A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials
Clinical Question What are the roles of antimalarial therapy prescribers and eye care specialists in regard to antimalarial dosing, screening for retinal toxic effects, and antimalarial treatment cessation? Bottom Line Antimalarial prescribers should prescribe antimalarial dosages at 5 mg/kg/d or less of actual body weight. A baseline retinal examination with optical coherence tomography should be performed within 6 months of starting antimalarial therapy to rule out confounding disease. Patients at low risk for retinopathy do not require annual screening until 5 years of antimalarial use. Eye care clinicians should not stop treatment with antimalarials because of equivocal findings, as retinopathy occurs slowly, and therefore there is time for repeated testing. Antimalarial treatment cessation should be a collaborative decision that involves the patient, the prescriber, and the eye care clinician and that focuses on patient values, the severity of the underlying disease, and the estimated risk of visual loss if treatment with the drug is continued. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- 1 September 2021
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 157 (9) , 1112-1113
A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials
Clinical Question What are the roles of antimalarial therapy prescribers and eye care specialists in regard to antimalarial dosing, screening for retinal toxic effects, and antimalarial treatment cessation? Bottom Line Antimalarial prescribers should prescribe antimalarial dosages at 5 mg/kg/d or less of actual body weight. A baseline retinal examination with optical coherence tomography should be performed within 6 months of starting antimalarial therapy to rule out confounding disease. Patients at low risk for retinopathy do not require annual screening until 5 years of antimalarial use. Eye care clinicians should not stop treatment with antimalarials because of equivocal findings, as retinopathy occurs slowly, and therefore there is time for repeated testing. Antimalarial treatment cessation should be a collaborative decision that involves the patient, the prescriber, and the eye care clinician and that focuses on patient values, the severity of the underlying disease, and the estimated risk of visual loss if treatment with the drug is continued. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- Open Access
- 1 July 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (7) , 1115-1116
Collaboration for the Management of Hydroxychloroquine
- 1 July 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (7) , 1115-1116
Open AccessCollaboration for the Management of Hydroxychloroquine
- 1 May 2021
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (5) , 386-387
Corrugated Purple Plaque on the Left Cheek: Answer
- 1 May 2021
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (5) , 386-387
Corrugated Purple Plaque on the Left Cheek: Answer
- 14 September 2020
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (5) , e54
Corrugated Purple-Black Plaque on the Left Cheek: Challenge
An abstract is unavailable. This article is available as a PDF only.
- 14 September 2020
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (5) , e54
Corrugated Purple-Black Plaque on the Left Cheek: Challenge
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 May 2020
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 156 (5) , 521-528
Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea
Morphea (localized scleroderma) is a rare sclerosing disorder of the skin and subcutaneous tissue that affects patients of all ages.1-3 Patients with extensive involvement unresponsive to phototherapy, with facial involvement, or with involvement traversing joints require systemic treatment to prevent disease progression and its associated morbidity. Experts recommend treatment with methotrexate (MTX) for these patients.2-6 This recommendation is based on a randomized, double-blind, placebo-controlled clinical trial in a pediatric population comparing the combination of prednisone for 3 months and MTX for 12 months vs prednisone alone for 3 months.7 Those who received MTX demonstrated improved skin scores and were less likely to experience disease relapse compared with those who received placebo. In addition, several small retrospective studies and a prospective study have further supported the value and safety of MTX, with or without systemic corticosteroids (SCSs), for the treatment of morphea.8-15 For some patients, treatment with MTX is ineffective, not well tolerated, or contraindicated. Studies suggest that approximately 25% to 30% of patients with morphea will not show clinical improvement with MTX.7,12 In this subset of patients, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)—referred to herein as mycophenolate—is recommended, although evidence supporting this practice is based on small case series.2,4,5
- 1 May 2020
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 156 (5) , 521-528
Open AccessEvaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea
Morphea (localized scleroderma) is a rare sclerosing disorder of the skin and subcutaneous tissue that affects patients of all ages.1-3 Patients with extensive involvement unresponsive to phototherapy, with facial involvement, or with involvement traversing joints require systemic treatment to prevent disease progression and its associated morbidity. Experts recommend treatment with methotrexate (MTX) for these patients.2-6 This recommendation is based on a randomized, double-blind, placebo-controlled clinical trial in a pediatric population comparing the combination of prednisone for 3 months and MTX for 12 months vs prednisone alone for 3 months.7 Those who received MTX demonstrated improved skin scores and were less likely to experience disease relapse compared with those who received placebo. In addition, several small retrospective studies and a prospective study have further supported the value and safety of MTX, with or without systemic corticosteroids (SCSs), for the treatment of morphea.8-15 For some patients, treatment with MTX is ineffective, not well tolerated, or contraindicated. Studies suggest that approximately 25% to 30% of patients with morphea will not show clinical improvement with MTX.7,12 In this subset of patients, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)—referred to herein as mycophenolate—is recommended, although evidence supporting this practice is based on small case series.2,4,5
- 25 May 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (5) , 1101-1103
Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies
- 25 May 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (5) , 1101-1103
Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies